Friday, April 12, 2013
Cardio3 BioSciences SA, of Mont-Saint-Guibert, Belgium, published results of its Phase II (C-CURE) trial in the Journal of the American College of Cardiology showing that therapy with C3BS-CQR-2 is feasible and safe with signals of benefit in chronic heart failure, and merits further evaluation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.